Side Effects Comparison# Retatrutide Side Effects# Phase 2 data (n=338 obesity trial): Nausea : ~25% at higher doses (8-12 mg) Diarrhea : ~20% Vomiting : ~15% Constipation : Common Decreased appetite : Common (pharmacological effect) Heart rate : Small increase (2-4 bpm), potentially related to glucagon component Injection site reactions : Mild, transient Discontinuation rate : 6-10% due to adverse events The glucagon receptor component introduces theoretical concerns for hyperglycemia (counterbalanced by GLP-1/GIP in practice), cardiovascular effects (chronotropic glucagon action), and hepatic effects, none of which produced safety signals in Phase 2 but require larger-scale monitoring
To be sure, I respect that weight loss is a struggle for these patients, and I prescribe and advocate for medication to help people lose weight
doi: 10.3389/fmicb.2022.979719 Received 27 June 2022 Accepted 14 September 2022 Published 06 October 2022 Volume 13 - 2022 Edited by Wanbo Tai, Shenzhen Bay Laboratory, China Reviewed by Lihui Guo, University of Amsterdam, Netherlands
Semaglutide, a weight loss drug Food and Drug Administration (FDA) approved in 2019, can be used to control appetite and reduce cravings for unhealthy food